Lifecore Biomedical (LFCR) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed SIGA Technologies (SIGA) over the past year, losing 4.5% versus a loss of 61.4%. Over five years, LFCR leads with a -34.4% price change compared with -54.1% for SIGA. Lifecore Biomedical is the larger company by market cap ($244.1 million vs $234.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFCR | SIGA |
|---|---|---|
| Share price | $6.44 | $3.26 |
| Market cap | $244.11M | $234.23M |
| 1-day change | -0.16% | -0.91% |
| YTD return | -21.27% | -46.64% |
| 1-year return | -4.45% | -61.37% |
| 5-year return | -34.35% | -54.15% |
| Forward P/E | — | 3.02 |
| EPS (TTM) | $-1.27 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.98 | $8.55 |
| 52-week low | $3.63 | $2.83 |
| Distance from 52-week high | -28.29% | -61.87% |
| Analyst consensus | hold | none |
| Avg. price target upside | -2.48% | — |
| Average volume | 264.01K | 731.22K |
| Shares outstanding | 37.91M | 71.85M |
| Employees | 382 | 49 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed SIGA by 56.9 percentage points over the past year.
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Healthcare · Drug Manufacturers - Specialty & Generic · 382 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Healthcare · Drug Manufacturers - Specialty & Generic · 49 employees
LFCR vs SIGA FAQ
Which is bigger, Lifecore Biomedical or SIGA Technologies?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $244.11M compared with $234.23M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, LFCR or SIGA?
LFCR returned -4.45% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Lifecore Biomedical and SIGA Technologies in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.